Skip to main content
. Author manuscript; available in PMC: 2018 Jan 15.
Published in final edited form as: J Immunol. 2016 Dec 19;198(2):718–728. doi: 10.4049/jimmunol.1601543

Figure 2. Human ERV-1 receptor is upregulated on type 2 diabetic neutrophils.

Figure 2

(A–C) The expression of ERV-1, BLT-1 and CD11b on human neutrophils was quantified by flow cytometry. (D) GIEMSA staining of isolated neutrophils showed similar morphology between the groups (upper panels) and immunofluorescence staining with anti-human ERV1 antibody (green) showed increased staining for ERV1 receptors. (E–F) CD18, CD14 receptor expression of healthy and diabetic neutrophils was quantified by flow cytometry. Results are expressed as mean fluorescence intensity (MFI). Statistical significance was evaluated by Wilcoxon test (n=82, healthy, n=41, T2D, n=41; ***p<0.001**** p<0.0001, ns = non-significant). Co-expression profile of ERV-1/BLT-1 receptor profile was quantified. (G) Double positive (ERV-1+/BLT-1+ neutrophils plotted and quantified by flow cytometry. (I) Double negative (ERV1−/BLT1−) neutrophils. (I–J) Double positive and negative CD11b/CD14 were quantified by flow cytometry. Results of marker co-expression are expressed as mean fluorescence intensity (MFI). Statistical significance was evaluated by Wilcoxon test (n=20, healthy, n=10, T2D, n=10; ***p<0.001**** p<0.0001, ns = non-significant).